Table 5 Relationships between use of psychotropics and risk of fractures in women

3-year follow-up

One BZD

22 (11.8)/46 (11.9)

1.0 (0.6-1.7)

.88

0.9 (0.5-1.5)

.66

-

-

One AP

9 (14.1)/46 (11.9)

1.3 (0.6-2.7)

.47

1.1 (0.5-2.2)

.83

-

-

One AD

3 (7.9)/46 (11.9)

0.7 (0.2-2.2)

.52

0.6 (0.2-1.9)

.36

-

-

Two or more BZDs

6 (16.2)/46 (11.9)

1.4 (0.6-3.4)

.40

1.3 (0.5-3.0)

.60

-

-

Two or more APs

3 (33.3)/46 (11.9)

3.8 (1.2-12.2)

.03

3.3 (1.0-10.7)

.05

1.0 (0.1-7.0)

.98

Two or more ADs

0 (0.0)/46 (11.9)

-

-

-

-

-

-

BZD and AP^b

5 (17.2)/46 (11.9)

1.7 (0.7-4.4)

.24

1.4 (0.6-3.6)

.46

-

-

BZD and AD^b

2 (8.0)/46 (11.9)

0.7 (0.2-2.9)

.62

0.6 (0.1-2.5)

.47

-

-

AP and AD^b

2 (15.4)/46 (11.9)

1.4 (0.3-5.7)

.65

1.1 (0.3-4.7)

.86

-

-

6-year follow-up

One BZD

33 (17.7)/76 (19.6)

1.0 (0.6-1.5)

.89

0.8 (0.6-1.3)

.43

-

-

One AP

13 (20.3)/76 (19.6)

1.2 (0.7-2.2)

.54

1.0 (0.6-1.8)

.98

-

-

One AD

5 (13.2)/76 (19.6)

0.7 (0.3-1.8)

.48

0.6 (0.2-1.5)

.30

-

-

Two or more BZDs

7 (18.9)/76 (19.6)

1.0 (0.5-2.2)

.95

0.9 (0.4-2.0)

.81

-

-

Two or more APs

3 (33.3)/76 (19.6)

2.9 (0.9-9.2)

.07

2.6 (0.8-8.3)

.10

-

-

Two or more ADs

0 (0.0)/76 (19.6)

-

-

-

-

-

-

BZD and AP^b

7 (24.1)/76 (19.6)

1.6 (0.8-3.6)

.21

1.4 (0.6-3.0)

.43

-

-

BZD and AD^b

3 (12.0)/76 (19.6)

0.7 (0.2-2.1)

.48

0.6 (0.2-1.8)

.34

-

-

AP and AD^b

4 (30.8)/76 (19.6)

1.9 (0.7-5.2)

.21

1.6 (0.6-4.4)

.38

-

-